Abstract
Menopause, an event often accompanied by symptoms such as hot flashes, can have a significant impact on a woman’s quality of life. A majority of women will experience hot flashes at some point in their life, given a normal life span. Despite multiple theories, the exact pathophysiology of hot flashes is not yet known. Many types of treatment options exist for women with hot flashes, from hormonal and nonhormonal pharmacological therapies to nonpharmacological interventions. Choosing the best treatment option for specific women involves knowledge of the risks and benefits of each treatment. Hormones (estrogen and/or progesterone, or tibolone alone) are still the most effective option available, resulting in an 80 to 90% reduction in hot flashes. The best nonhormonal treatment to date is in the class of newer antidepressants that comprises various selective reuptake inhibitors; for example, venlafaxine provides about a 60% reduction in hot flashes. This article provides evidence-based information about available treatment options for hot flash management, with special consideration of populations such as breast cancer survivors.
Similar content being viewed by others
References
Harlow BL, Signorello LB. Factors associated with early menopause. Maturitas 2000; 35: 3–9
Lower EE, Blau R, Gazder P, et al. The risk of premature menopause induced by chemotherapy for early breast cancer. J Women’s Health Gend Based Med 1999; 8: 949–54
Roberts J, Chambers LF, Blake J, et al. Psychosocial adjustment in post-menopausal women. Can J Nursing Res 1992; 24: 29–46
Hammond CB, editor. Therapeutic options for menopausal health monograph. Durham (NC): Duke University Medical Center, Department of Obstetrics/Gynecology, and BMK Associates, LLC, 1998
Kronenberg F. Hot flashes: epidemiology and physiology. In: Flint M, Kronengerg F, Utian W, editors. Annals of the New York Academy of Sciences. New York (NY): New York Academy of Sciences, 1990: 52–86
Finck G, Barton DL, Loprinzi CL, et al. Definitions of hot flashes in breast cancer survivors. J Pain Symptom Manage 1998; 16: 327–33
Levine-Silverman R. The menopausal hot flash: a procrustean bed of research. J Adv Nursing 1989; 14: 939–49
Koster A. Hormone replacement therapy: use patterns in 51-year-old Danish women. Maturitas 1990; 12: 345–56
Rabin DS, Cipparrone N, Linn E, et al. Why menopausal women do not want to take hormone replacement therapy. Menopause 1999; 6: 61–7
Greendale GA, Lee NP, Arriola ER. The menopause. Lancet 1999; 353: 571–80
Daly E, Gray A, Barlow D, et al. Measuring the impact of menopausal symptoms on quality of life. BMJ 1993; 307: 836–40
Stein KD, Jacobsen PB, Hann DM, et al. Impact of hot flashes on quality of life among postmenopausal women being treated for breast cancer. J Pain Symptom Manage 2000; 19: 436–5
Pansini F, Albertazzi P, Bonaccorsi G, et al. The menopausal transition: a dynamic approach to the pathogenesis of neurovegetative complaints. Eur J Obstet Gynecol Reprod Biol 1994; 57: 103–9
Erlik Y, Tataryn IV, Meldrum DR, et al. Association of waking episodes with menopausal hot flushes. JAMA 1981; 245: 1741–4
Berg J, Taylor D. Symptom experience of Filipino American midlife women. Menopause 1999; 6(2): 105–14
Carpenter JS, Andrykowski MA. Menopausal symptoms in breast cancer survivors. Oncol Nurs Forum 1999; 26: 1311–7
Loprinzi CL, Zahasky K, Sloan J, et al. Tamoxifen-induced hot flashes. Clin Breast Cancer 2000; 1(1): 20–4
Savage M, Brengelmann G. Control of skin blood flow in the neutral zone of human body temperature regulation. J Appl Physiol 1996; 80(4): 1249–57
Wyon YAM, Spetz ACE, Theodorsson GE, et al. Concentrations of calcitonin gene-related peptide and neuropeptide Y in plasma increase during flushes in postmenopausal women. Menopause 2000; 7: 25–30
Ganong W. Review of medical physiology. San Francisco (CA): Appleton & Lange, 1993
Tataryn IV, Lomax P, Bajorek JG, et al. Postmenopausal hot flushes: a disorder of thermoregulation. Maturitas 1980; 2: 101–7
Freedman RR. Biochemical, metabolic, and vascular mechanisms in menopausal hot flashes. Am Soc Reprod Med 1998; 70: 332–7
Wyon Y, Frisk J, Lundeberg T, et al. Postmenopausal women with vasomotor symptoms have increased urinary excretion of calcitonin gene-related peptide. Maturitas 1998; 30: 289–34
Bachman G. Vasomotor flushes in menopausal women. Am J Obstet Gynecol 1999; 180: S312–6
Notelovitz M, Lenihan JP, McDermott M, et al. Initial 17 betaestradiol dose for treating vasomotor symptoms. Obstet Gynecol 2000; 95: 726–31
Nand SL, Webster MA, Baber R, et al. Menopausal symptom control and side-effects on continuous estrone sulfate and three doses of medroxyprogesterone acetate. Climacteric 1998; 1: 211–8
Lobo RA, McCormick W, Singer F, et al. Depo-medroxyprogesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women. Obstet Gynecol 1984; 63: 1–5
Greendale GA, Reboussin BA, Hogan P, et al. Symptom relief and side effects of postmenopausal hormones: results from the postmenopausal estrogen/progestin interventions trial. Obst Gynecol 1998; 92: 982–8
Lewis CE, Groff JY, Herman CJ, et al. Overview of women’s decision making regarding elective hysterectomy, oophorectomy, and hormone replacement therapy. J Women’s Health Gend Based Mede 2000; 9Suppl. 2: S5–14
Doren M, Schneider HP. The impact of different HRT regimens on compliance. Int J Fertil Menopausal Stud 1996; 41: 29–39
Lauver DR, Settersten L, Marten S, et al. Explaining women’s intentions and use of hormones with menopause. Res Nurs Health 1999; 22: 309–20
Castelo-Branco C, Figueras F, Sanjuan A, et al. Long-term compliance with estrogen replacement therapy in surgical postmenopausal women: benefits to bone and analysis of factors associated with discontinuation. Menopause 1999; 6: 307–11
Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994; 331: 347–52
Morrison JC, Martin DC, Blair RA, et al. The use of medroxyprogesterone acetate for relief of climacteric symptoms. Am J Obstet Gynecol 1980; 138: 99–104
Bullock JL, Massey FM, Gambrell RD. Use of medroxyprogesterone acetate to prevent menopausal symptoms. Obstet Gynecol 1975; 46: 165–98
Quella SK, Loprinzi CL, Sloan JA, et al. Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer 1998; 82: 1784–8
Bertelli F, Venturini M, Del Mastro L, et al. Depot intramuscular medroxyprogesterone acetate (MAP) vs. oral megestrol acetate (MA) for the treatment of hot flashes in breast cancer survivors: results of GONO (Gruppo Oncologico Nord Ovest) MIG-4 Phase III Trial [abstract 2286]. ASCO 1999; 18: 592a
Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000; 283: 485–91
Dew J, Beller E, Magarey C, et al. A cohort study of hormone replacement therapy given to women previously treated for breast cancer. Climacteric 1998; 1: 137–42
Natrajan PK, Soumakis K, Gambrell RD. Estrogen replacement therapy in women with previous breast cancer. Am J Obstet Gynecol 1999; 181: 288–95
Gundersen S, Kvinnsland S, Lundgren S, et al. Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat 1990; 17: 45–50
Martoni A, Longhi A, Canova N, et al. High-dose medroxyprogesterone acetate versus oophorectomy as first-line therapy of advanced breast cancer in premenopausal patients. Oncology 1991; 48: 1–6
Pronzato P, Brema F, Amoroso D, et al. Megestrol acetate: phase II study of a single daily administration in advanced breast cancer. Breast Cancer Res Treat 1990; 17: 51–4
Gelfand M. Role of androgens in surgical menopause. Am J Obstet Gynecol 1999; 180 (3 Pt 2): S325–327
Albertazzi P, DiMicco R, Zanardi E. Tibolone: a review. Maturitas 1998; 30: 295–305
De Aloysio D, Fabiani AG, Mauloni M, et al. Use of Org OD 14 for the treatment of climacteric complaints. Maturitas 1987; Suppl. 1: 49–65
Hammar M, Christau S, Nathorst-Boos J, et al. Double-blind, randomized trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 1998; 105(8): 904–11
Volpe A, Facchinetti F, Grasso A, et al. Benefits and risks of different hormonal replacement therapies in post-menopausal women. Maturitas 1986; 8: 327–34
Lindsay R, Hart D, Kraszewski A. Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. BMJ 1980; 280: 1207–9
Doren M, Rubig A, Coelingh Bennick HJ, et al. Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy. Menopause 1999; 6(4): 299–306
Egarter C, Sator M, Berghammer P, et al. Efficacy, tolerability and rare side effects of tibolone treatment in postmenopausal women. Int J Gynaecol Obstet 1999; 64(3): 281–6
Moore RA. Livial: a review of clinical studies. Br J Obstet Gynaecol 1999 106Suppl. 19: 1–21
Wren BG, Brown LB. A double-blind trial with clonidine and a placebo to treat hot flushes. Med J Aust 1986; 144: 369–70
Pandya KJ, Raubertas RF, Flynn PJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 2000; 132: 788–93
Goldberg RM, Loprinzi CL, O’Fallon JR, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. Am Soc Clin Oncol 1994; 12: 155–8
Laufer L, Erlik Y, Meldrum D, et al. Effect of clonidine on hot flashes in postmenopausal women. Obstet Gynecol 1982; 60: 583–6
Coope J, Williams S, Patterson JS. A study of the effectiveness of propranolol in menopausal hot flushes. Br J Obstet Gynecol 1978; 85: 472–5
Hammond MG, Hatley L, Talbert LM. A double-blind study to evaluate the effect of methyldopa on menopausal vasomotor flushes. J Clin Endocrinol Metab 1984; 58: 1158–60
Hodgson BB, Kizior R. Saunders nursing drug handbook 2000. Philadelphia (PA): WB Saunders Co., 2000
Bergmans MGM, Merkus JMWM, Corbey RS, et al. Effect of bellergal retard on climacteric complaints: a double-blind, placebo-controlled study. Maturitas 1987; 9: 227–34
Lebherz TB, French L. Nonhormonal treatment of the menopausal syndrome: a double-blind evaluation of an autonomic system stabilizer. Obstet Gynecol 1969; 33: 795–9
David A, Don R, Tajchner G, et al. Veralipride: alternative antidopaminergic treatment for menopausal symptoms. Am J Obstet Gynecol 1988; 158: 1107–15
Vercellini P, Vendola N, Colombo A, et al. Veralipride for hot flashes during gonadotropin-releasing hormone agonist treatment. Gynecol Obstet Invest 1992: 34: 102–4
Wesel S, Bourguignon RP, Bosuma WB. Veralipride versus conjugated oestrogens: a double-blind study in the management of menopausal hot flushes. Curr Med Res Opin 1984; 8: 696–700
Verbeke K, Dhont M, Vandekerkhove D. Clinical and hormonal effects of long-term veralipride treatment in postmenopausal women. Maturitas 1988; 10: 225–30
Melis GB, Gamacciani M, Cagnacci A, et al. Effects of the dopamine antagonist veralipride on hot flushes and luteinizing hormone secretion in postmenopausal women. Obstet Gynecol 1988; 72: 688–92
Barton DL, Loprinzi CL, Quella SK, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 1998; 16: 495–500
Oddens BJ. The climacteric cross-culturally: the International Health Foundation South-East Asia study. Maturitas 1994; 19: 155–6
Quella SK, Loprinzi CL, Barton DL, et al. Evaluations of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group Trial. J Clin Oncol 2000; 18: 1068–74
Scambia G, Mango D, Signorile PG, et al. Clinical effects of a standardized soy extract in postmenopausal women: a pilot study. Menopause 2000; 7: 105–11
Upmalis DH, Lobo R, Bradley L, et al. Vasomotor symptom relief by soy isflavone extract tablets in postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. Menopaus 2000; 7: 236–42
Lieberman S. A review of the effectiveness of cimicifuga racemosa (black cohosh) for the symptoms of menopause. J Women’s Health 1998; 7: 525–9
Pepping J. Black cohosh: cimicifuga racemosa. Am J Health Syst Pharm 1999; 56: 1400–2
Liske E. Therapeutic efficacy and safety of cimifuga racemosa for gynecologic disorders. Adv Ther 1998; 15: 45–53
Jacobson J, Toxel A, Evans J, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol 2001; 19(10): 2739–45
Loprinzi CL, Pisansky TM, Fonseca R, et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 1998; 16: 2377–81
Loprinzi CL, Kugler JW, Sloan J, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000; 356: 2059–63
Loprinzi CL, Quella SK, Sloan JA. Preliminary data from a randomized evaluation of fluoxetine (Prozac) for treating hot flashes in breast cancer survivors [abstract]. Breast Cancer Res Treat 1999; 57: 34
Stearns V, Isaacs C, Rowland J, et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol 2000; 11: 17–22
Roth AJ, Scher HI. Sertraline relieves hot flashes secondary to medical castration as treatment of advanced prostate cancer. Psychooncology 1998; 7: 129–32
Germaine LM, Freedman RR. Behavioral treatment of menopausal hot flashes: evaluation by objective methods. J Consult Clin Psychol 1984; 52: 1072–9
Freedman RR, Woodward S. Behavioral treatment of menopausal hot flushes: evaluation by ambulatory monitoring. Am J Obstet Gynecol 1992; 167: 436–9
Wijma K, Melin A, Nedstrand E, et al. Treatment of menopausal symptoms with applied relaxation: a pilot study. J Behav Ther Exp Psychiatry 1997; 28(4): 251–61
Ganz PA, Greendale GA, Petersen L, et al. Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J Natl Cancer Inst 2000; 92: 1054–64
Consensus Statement. Treatment of estrogen deficiency symptoms in women surviving breast cancer. J Clin Endocrinol Metab 1998; 83(6): 1993–2000
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Barton, D., Loprinzi, C. & Wahner-Roedler, D. Hot Flashes. Drugs & Aging 18, 597–606 (2001). https://doi.org/10.2165/00002512-200118080-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002512-200118080-00004